KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

@article{Boeck2013KRASMS,
  title={KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer},
  author={Stefan Hubert Boeck and Andreas Jung and Ruediger Paul Laubender and Jens Neumann and Rosalind Egg and Clara Goritschan and Steffen Ormanns and Michael Haas and Dominik Paul Modest and Thomas W. Kirchner and Volker Heinemann},
  journal={Journal of Gastroenterology},
  year={2013},
  volume={48},
  pages={544-548}
}
It has not yet been defined if KRAS has a prognostic value or is a predictive biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC). AIO-PK0104 was a phase III trial comparing gemcitabine/erlotinib followed by capecitabine with capecitabine/erlotinib followed by gemcitabine in advanced PC. For this post hoc subgroup analysis, biomarker data on the KRAS exon 2 mutation status were correlated with objective response to 1st-line therapy and with overall survival after start of… CONTINUE READING